<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://dirros.openscience.si/IzpisGradiva.php?id=19163"><dc:title>Premalignant gastric lesions in patients included in National colorectal cancer screening</dc:title><dc:creator>Tepeš,	Bojan	(Avtor)
	</dc:creator><dc:creator>Šeruga,	Maja	(Avtor)
	</dc:creator><dc:creator>Vujasinović,	Miroslav	(Avtor)
	</dc:creator><dc:creator>Urlep,	Dejan	(Avtor)
	</dc:creator><dc:creator>Ljepovic,	Liljana	(Avtor)
	</dc:creator><dc:creator>Brglez Jurečič,	Nataša	(Avtor)
	</dc:creator><dc:creator>Forte,	Alenka	(Avtor)
	</dc:creator><dc:creator>Kek-Ljubec,	Anita	(Avtor)
	</dc:creator><dc:creator>Skvarč,	Miha	(Avtor)
	</dc:creator><dc:subject>Helicobacter pylori</dc:subject><dc:subject>gastropanel</dc:subject><dc:subject>atrophy</dc:subject><dc:subject>Slovenia</dc:subject><dc:subject>intestinal metaplasia</dc:subject><dc:subject>gastric cancer</dc:subject><dc:subject>SVIT</dc:subject><dc:description>Background. Gastric cancer is the fifth most common malignancy in the world with almost one million new cases annually. Helicobacter pylori infection causes 89% of all gastric cancers. Premalignant lesions (atrophy and intestinal metaplasia) develop after several decades of inflammation. Secondary prevention with gastroscopy is possible, but it is costly and has a low compliance rate. Alternative procedures like serology testing for pepsinogen I and II and pepsinogen I/II ratio are available to select patients for surveillance gastroscopies. Patients and methods. In seven outpatient endoscopic units, 288 patients (154 men; 53.5%), average age 60.68 years, tested positive in National colorectal cancer screening programme SVIT, were included in the study. Gastropanel (BioHit, Finland) was used as a serologic biopsy method. Results. We found 24 patients (12 men, mean age 63.7 years) with pepsinogen (pepsinogen I/II &lt; 3 and/or pepsinogen I &lt; 30 %g/L). Premalignant changes were found on gastric biopsies in 21 patients (7.3% incidence). Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) % 1 was found in 20 patients; Operative Link for Gastritis Assessment (OLGA) % 1 was found in 19 patients. Combined accuracy for preneoplastic lesions in Gastropanel positive patients was 87.5%. H. pylori seropositivity was found in 219 patients (76%). Only 24% of our population had normal results. Conclusions. Gastropanel test has proven to be a reliable non-invasive test for advanced gastric preneoplastic lesions that can select patients for further gastroscopy. We found high H. pylori seropositivity in older age groups in Slovenia.</dc:description><dc:publisher>Association of Radiology and Oncology</dc:publisher><dc:date>2018</dc:date><dc:date>2024-07-02 13:13:37</dc:date><dc:type>Neznano</dc:type><dc:identifier>19163</dc:identifier><dc:source>Ljubljana</dc:source><dc:language>sl</dc:language><dc:rights>by Authors</dc:rights></rdf:Description></rdf:RDF>
